Yeah I really confused used things in my prior post. Next time, I should wait to reply till I am more alert :-). I don't disagree with 60 million market cap its not a lot priced in especially if they have a few drug candidates with some potential. Probably even a good business model to steal compounds that have been sitting (this one on Ligand's shelf and 3rd company with it) because they weren't tried in the right indication. Just for me seemed like an ERA has some safety risk and not clear it'll work well enough considering there are some other (granted suboptimal) treatment options.
Market Data 
Markets 
AI
